Insider Transactions in Q1 2021 at Zentalis Pharmaceuticals, Inc. (ZNTL)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2021
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
4,720
-7.41%
|
$212,400
$45.24 P/Share
|
|
Mar 03
2021
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
3,700
-5.49%
|
$166,500
$45.07 P/Share
|
|
Mar 01
2021
|
Epperly Melissa B, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,083
-1.08%
|
$126,403
$41.67 P/Share
|
|
Mar 01
2021
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
10,000
-1.74%
|
$410,000
$41.69 P/Share
|
|
Mar 01
2021
|
Anthony Y Sun President & CEO |
SELL
Open market or private sale
|
Direct |
26,794
-0.75%
|
$1,098,554
$41.53 P/Share
|
|
Mar 01
2021
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
4,210
-5.88%
|
$172,610
$41.65 P/Share
|
|
Feb 11
2021
|
Cam Gallagher President, Interim CFO |
BUY
Grant, award, or other acquisition
|
Direct |
13,750
+1.19%
|
-
|
|
Feb 11
2021
|
Dimitris Voliotis SVP, Clinical Development |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+50.0%
|
-
|
|
Feb 11
2021
|
Anthony Y Sun President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+2.38%
|
-
|
|
Feb 11
2021
|
Kevin D. Bunker Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,750
+1.76%
|
-
|
|
Feb 11
2021
|
Alexis Pinto Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+50.0%
|
-
|
|
Feb 11
2021
|
Epperly Melissa B, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+4.97%
|
-
|
|
Feb 01
2021
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
4,210
-2.82%
|
$155,770
$37.56 P/Share
|
|
Feb 01
2021
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
10,000
-0.88%
|
$370,000
$37.71 P/Share
|
|
Feb 01
2021
|
Epperly Melissa B, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,083
-0.56%
|
$114,071
$37.89 P/Share
|
|
Feb 01
2021
|
Anthony Y Sun President & CEO |
SELL
Open market or private sale
|
Direct |
26,794
-0.5%
|
$991,378
$37.82 P/Share
|
|
Jan 04
2021
|
Epperly Melissa B, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,083
-0.28%
|
$157,233
$51.97 P/Share
|
|
Jan 04
2021
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
8,420
-2.59%
|
$429,420
$51.95 P/Share
|
|
Jan 04
2021
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
26,567
-0.64%
|
$1,354,917
$51.81 P/Share
|
|
Jan 04
2021
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
10,000
-0.43%
|
$510,000
$51.88 P/Share
|
|
Jan 04
2021
|
Anthony Y Sun President & CEO |
SELL
Open market or private sale
|
Direct |
26,794
-0.37%
|
$1,366,494
$51.85 P/Share
|